Each distinct association signal was represented by an index variant in the GCTA joint regression model based on (i) summary statistics from a combined meta-analysis of 46,868 cases and 172,714 controls of European ancestry and (ii) reference genotype data from GoDARTS (3,298 cases and 3,708 controls of European ancestry from the UK) to approximate LD across fine-mapping regions. Insertion-deletion alleles are coded as reference (R) or deletion (D). Chr., chromosome; RAF, risk allele frequency; OR, odds ratio for the risk allele; CI, confidence interval.
a
The previously reported T2D GWAS SNP at the HNF4A locus (rs4812829) is not included in the fine-mapping region. However, the reported index variant, rs1800961, is independent of the GWAS-identified SNP and thus represents a new, distinct association signal at this locus.
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A r t i c l e s a potential distinct association signal, located upstream of the recombination interval in the noncoding CDKN2B-AS1 (ANRIL) transcript. However, our conditional analyses indicate that the association in this region can be fully explained by the two index SNPs in the recombination interval, which, when considered together, fully extinguish the CDKN2B-AS1 signal ( Supplementary Fig. 4 ). The index variants at DGKB and MC4R also confirm previously reported distinct association signals at these loci in European-ancestry GWAS metaanalyses 4 . At the GIPR locus, the two index variants (rs2238689, P J = 8.3 × 10 −16 ; rs4399645, P J = 1.4 × 10 −8 ) are not in strong LD with the previously reported 4 lead SNP (rs8108269; r 2 = 0.43 with rs2238689 and 0.00 with rs4399645) but together can better explain the T2D association signal in this region. Finally, we observed a new distinct association signal at the HNF4A locus, represented by the coding index variant rs1800961 (P J = 1.4 × 10 −9 , encoding HNF4A p.Thr139Ile, referred to as p.Thr130Ile in some previous studies 29 ). Unfortunately, this finemapping region was included on the Metabochip for high-density lipoprotein cholesterol 15, 30 (Supplementary Table 3 ) and does not include the previously reported 4 lead T2D SNP at this locus, rs4812829, precluding conditional analyses in these data. However, rs4812829 is not in LD with our index variant (r 2 = 0.02), suggesting that there are at least two distinct T2D association signals at the HNF4A locus.
Of the 49 distinct association signals achieving locus-wide significance across the T2D loci represented on the Metabochip (five at KCNQ1, three at HNF1A, two each at CDKN2A-CDKN2B, DGKB, MC4R and GIPR, and one each at the remaining loci), only three index variants are not common ( Supplementary Fig. 5 and Supplementary  Table 6 ): rs1800574 (MAF = 2.2%, odds ratio (OR) = 1.21) for one signal at the HNF1A locus; rs1800961 (MAF = 3.9%, OR = 1.16) at the HNF4A locus; and rs17066842 (MAF = 4.8%, OR = 1.12) for one signal at the MC4R locus.
Localizing variants driving T2D association signals
We used statistical evidence of association from the meta-analysis of Metabochip studies to construct 99% credible sets of variants 28 that are most likely to drive the 49 distinct signals (Online Methods, Supplementary Fig. 6 and Supplementary Table 8 ). For ten distinct association signals mapping to nine loci, the 99% credible set included no more than ten variants (Table 2 and Supplementary Table 9) .
The greatest refinement was observed at the MTNR1B locus, where the credible set included only the index variant, rs10830963, accounting for more than 99.8% of the posterior probability of driving the association signal (π C ). Small credible sets were also observed for the association at TCF7L2 (three variants, indexed by rs7903146, mapping to 4.3 kb) and one signal at KCNQ1 (three variants, indexed by rs74046911, mapping to just 200 bp). The 99% credible sets for both distinct association signals at CDKN2A-CDKN2B together included just 11 variants in total and map to less than 2 kb.
We performed functional annotation of credible set variants to search for evidence that association signals are driven by coding alleles. Across the 49 signals, only nine coding variants attained π C >1% (Supplementary Table 10 ), including six previously reported nonsynonymous T2D risk alleles at PPARG 6 , KCNJ11-ABCC8 (refs. 7,31,32) , SLC30A8 (refs. 8,33) and GCKR 9, 34 . The remaining three coding alleles were the index variants for association signals mapping to HNF4A (rs1800961, encoding p.Thr139Ile, π C = 97.4%) and HNF1A (rs1169288, encoding p.Ile27Leu, π C = 75.5%; rs1800574, encoding p.Ala98Val, π C = 34.0%). Our findings are supported by earlier studies, which reported nominal evidence for association of these three coding variants with T2D and defects in insulin secretion in vivo and demonstrated reduced transcriptional activity of HNF1A target genes using in vitro assays 29, 35 . These data provide strong evidence that HNF4A and HNF1A are T2D effector transcripts at these loci, a view further supported by the known impact of rare, loss-of-function mutations in these genes on maturity-onset diabetes of the young 36, 37 . Given the nearly complete coverage of common and low-frequency variants in fine-mapping regions after 1000 Genomes Project imputation, it is unlikely that additional distinct signals in the established T2D susceptibility loci represented on the Metabochip are driven by coding variation with MAF ≥0.5%, confirming reports that these associations are most likely mediated by effects on gene regulation 10, 13, 14, 38 .
Regulatory mechanisms underlying T2D association signals
We sought to understand the regulatory mechanisms through which variants at the 39 established T2D susceptibility loci influence disease by intersecting the 99% credible sets for each distinct association signal with chromatin immunoprecipitation sequence (ChIP-seq) data for 165 transcription factors, chromatin state maps from 12 cell types and long noncoding RNA transcripts from 25 cell types (Online 
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Methods and Supplementary Table 11).
We applied an enrichment procedure that compared the mean posterior probability of driving the association signal for credible set variants directly overlapping sites for each regulatory annotation with a null distribution obtained from randomly shifted site locations within 100 kb in either direction of the original element location. We first applied this procedure to chromatin state and noncoding RNA elements using the 19,266 credible set variants for all 49 distinct association signals (Supplementary Fig. 7 ). Using Bonferroni correction for the 37 tested cell type annotations (P < 0.0014), variants in pancreatic islet enhancer elements 14 had significantly higher posterior probability of driving association signals than expected from the null distribution (1.97-fold enrichment, P = 0.00022). We also observed nominal evidence for enrichment of the posterior probability of driving association signals among variants in human islet and hepatocellular carcinoma (HepG2) promoter elements 10, 14 (P = 0.0052 and 0.0064, respectively). However, there was no corresponding enrichment of variants in regulatory elements for other cell types or in noncoding transcripts. These results are consistent with previous studies supporting a contribution of regulatory enhancer and promoter variants to T2D susceptibility in specific cell types [11] [12] [13] [14] .
We next sought to gain insight into the transcription factors these regulatory variants perturb and applied the same procedure to ChIPseq binding data for 165 proteins ( Fig. 1 and Supplementary Fig. 8 ). Using Bonferroni correction for the 165 proteins tested (P < 0.00030), the 89 credible set variants overlapping 57 FOXA2 ChIP-seq binding sites, assayed in human HepG2 (ref. 10 ) and islet 14 cells, had significantly higher posterior probability of driving association signals than expected from the null distribution (8.24-fold enrichment, P = 0.00028). The enrichment of FOXA2 ChIP-seq sites was exclusive to sites shared with at least one other factor (9.18-fold enrichment, P = 0.00028) in comparison to those that were not shared (1.12-fold enrichment, P = 0.11). Enrichment for FOXA2 binding was also more pronounced among sites identified in pancreatic islets (15.43-fold enrichment, P = 0.00045) than in those identified in HepG2 cells (4.55-fold enrichment, P = 0.011). To exclude the possibility that the enrichment in HepG2 cells was driven by artifacts due to HepG2 being a cultured cell line, we compared the FOXA2 sites in HepG2 cells to those previously assayed in primary liver 39 . We observed significant intersection of the HepG2 and liver FOXA2 sites that overlapped credible set variants (P = 1.5 × 10 −9 ). Consequently, we detected similar FOXA2 binding site enrichment among sites detected in liver (3.63-fold enrichment, P = 0.061) to that observed in HepG2 cells. We also compared FOXA2 ChIP-seq sites, across the genome, from liver, HepG2 and islet cells (Supplementary Fig. 9 ). The number of sites varied across the cell types (8,023 for liver, 40,866 for HepG2 cells and 27,291 for islets), likely owing, in part, to technical differences, including in sequencing platform, depth and read length. However, the intersection of FOXA2 sites between each pair of cell types was highly significant (P < 2.2 × 10 −16 ).
Given the preponderance of T2D-associated variants in islet enhancers, we next tested to what extent enrichment of FOXA2 binding is driven by colocalization of variants with these genomic features 14 . Variants in FOXA2-bound sites were not enriched for posterior probability of driving association signals after removing enhancer sites (0.36-fold enrichment, P = 0.69). Conversely, variants in islet enhancers remained nominally enriched when FOXA2-bound sites were removed (1.65-fold enrichment, P = 0.014). These results suggest that FOXA2 binding assayed by ChIP-seq, at a 
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A r t i c l e s subset of enhancer element locations that are often shared by other proteins, is a genomic marker of variants with an increased posterior probability of driving T2D association signals.
Having demonstrated global over-representation for FOXA2 ChIPseq binding by considering all loci simultaneously, we applied the same procedure to the 99% credible sets of each distinct association signal separately to identify those with the strongest evidence for local enrichment (Fig. 1) . We observed over-representation of credible set variants in islet or HepG2 FOXA2-bound sites for 19 association signals, 15 of which attained nominal significance (P < 0.05). A total of 41 credible set variants at these 19 distinct association signals overlapped a FOXA2 ChIP-seq site in at least one of the two cell types (Supplementary Table 12 ). Of these, 12 variants were predicted to disrupt de novo recognition motifs (for FOXA2 and other factors) that were enriched in FOXA2-bound sequence (Table 3 and  Supplementary Table 13 ). The mean posterior probability of driving the association (p C ) for these 12 variants was 22.0% on the basis of genetic fine mapping ( Fig. 1) , more than four times greater than for those in FOXA2 ChIP-seq sites that were not motif disrupting at the same signals (mean π C = 5.2%, P = 0.024). Furthermore, 11 of these 12 variants also overlapped an enhancer element in islets (nine variants) or HepG2 cells (six variants), indicating that they are in transcriptionally active regions ( Table 3) . They include two variants with experimentally validated differences in regulatory activity: rs7903146 (π C = 77.6%) at TCF7L2 (ref. 40 ) and rs11257655 (π C = 21.1%) at CDC123 (ref. 41) . They also include rs10830963, the index variant at the MTNR1B locus, which accounts for 99.8% of the posterior probability of driving the association signal on the basis of genetic fine mapping. These results suggest that FOXA2 binding patterns can be used to highlight specific variants that are potentially causal for T2D susceptibility through altered regulatory binding.
Altered regulatory activity of the MTNR1B credible variant
To demonstrate how local enrichment of FOXA2 binding can be used to highlight regulatory mechanisms through which credible set variants might influence T2D susceptibility, we focused on the MTNR1B Figure 2 The lone variant in the 99% credible set at the MTNR1B locus affects FOXA2-bound enhancer activity. (a) The intronic variant rs10830963 has 99.8% posterior probability of driving the association signal at the MTRN1B locus. This variant overlaps a FOXA2 binding site, and the G risk allele is predicted to create a de novo recognition motif that closely matches the NEUROD1 consensus motif. (b) EMSA of 25-bp fragments encompassing either allele of rs10830963 in EndoC-βH1 cell extracts. Proteins were bound to both alleles. In the presence of an antibody to NEUROD1, only the signal corresponding to the risk allele was supershifted; in the presence of an unlabeled probe with the NEUROD1 consensus motif, the signal was competed away. NE, nuclear extract. (c,d) The 224-bp sequence surrounding each allele of rs10830963 was cloned into a luciferase reporter construct containing a minimal promoter and tested for luciferase activity in EndoC-βH1 (c) and HepG2 (d) cells (n = 3 independent experiments performed in triplicate for each cell type). Results are presented as means ± s.e.m. The risk allele had significantly increased enhancer activity over the protective allele in both forward and reverse orientations of the element in both cell types. npg A r t i c l e s locus. Variants mapping to this region have among the strongest known effects on both T2D risk 6 and fasting plasma glucose concentration 42 , and physiological data indicate an effect of MTNR1B on both insulin secretion and insulin action 43 . The lone credible variant in the MTNR1B region, rs10830963, overlaps a FOXA2 ChIP-seq binding site, and the risk allele, G, is predicted to create a recognition motif that matches the consensus sequences of NEUROD1 and several other factors ( Fig. 2 and Supplementary Table 13 ). We tested in silico predictions of protein binding at rs10830963 via electrophoretic mobility shift assay (EMSA) with 25-bp probe fragments centered on each allele in human pancreatic islet β cell (EndoC-βH1) 44 or human liver HepG2 cell extracts. We observed allelespecific binding patterns with extracts from both cell lines ( Fig. 2 and Supplementary Fig. 10 ).
To determine the specific protein(s) bound at each allele, we then performed supershift experiments using antibodies directed against NEUROD1, FOXA2 and three other factors (TAL1, PTF1A and YY1) whose consensus binding sequences resemble the recognition motif (Online Methods). We observed a shift in the presence of antibody to NEUROD1 for the signal corresponding to the risk allele in EndoC-βH1 extracts, which could be competed away by an excess of unlabeled probe with the NEUROD1 consensus sequence (Fig. 2) . None of the antibodies tested (including to NEUROD1) shifted the signal corresponding to the risk allele in HepG2 cell extracts (Supplementary Fig. 10 ). These results demonstrate that, in vitro, the risk allele of rs10830963 preferentially binds NEUROD1 in islet-derived cells and binds a protein not identified from known recognition motifs in liver-derived cells.
To relate allelic differences in protein binding to genomic activity at this site, we cloned the 224-bp region surrounding rs10830963 into a luciferase reporter vector containing a minimal promoter and tested its enhancer activity in the EndoC-βH1 and HepG2 cell lines. Consistent with in silico predictions, we observed a significant (P < 0.05) increase in luciferase expression for the element with the risk allele in comparison to the one with the protective allele in both cell lines (Fig. 2) . Furthermore, RNA sequencing (RNA-seq) data reported from human islets have linked the T2D risk allele of rs10830963 to increased expression of MTNR1B 45, 46 . Taken together, these results suggest that the G allele of rs10830963 increases T2D risk through increased FOXA2-bound enhancer activity, potentially mediated through NEUROD1 binding in islets, and consequently higher expression of MTNR1B.
Candidate effector genes at FOXA2-enriched T2D signals
We hypothesized that the locus-specific effects in mouse transcription factor knockout models would mimic patterns of binding enrichment at human disease-associated loci. We thus attempted to relate FOXA2 binding at the 19 FOXA2-enriched association signals (Fig. 1) to target effector genes using previously reported pancreatic islet expression profiles from wild-type and Foxa1 and Foxa2 double-null mice 47 (Online Methods). Syntenic genes mapping within 500 kb of the credible sets for the 19 FOXA2-enriched signals were significantly downregulated (45.2% decrease) in Foxa1 and Foxa2 double-knockout mice (Supplementary Fig. 11 ) in comparison to genes across the genome (0.021% increase; P = 0.012), whereas those mapping within 500 kb of the other 30 T2D association signals were not significantly downregulated (2.25% decrease; P = 0.20). We observed a consistent downregulation (39.6% decrease) when considering only the genes mapping closest to each FOXA2-enriched signal, in comparison to those across the genome (0.021% increase; P = 0.0021). Thus, data related to altered gene expression in Foxa1 and Foxa2 double-knockout mice support patterns of FOXA2 binding site enrichment in humans.
We next identified specific genes at the 19 FOXA2-enriched association signals whose mouse counterparts were downregulated in Foxa1 and Foxa2 double-knockout mice, as these might represent effector transcripts for these loci (Supplementary Table 14) .
DISCUSSION
We have undertaken comprehensive fine mapping of 39 established T2D susceptibility loci in 27,206 cases and 57,574 controls of European ancestry and have demonstrated that the existence of multiple distinct association signals in these regions is a common phenomenon. Index variants for just three of the 49 distinct association signals are not common, despite nearly complete coverage of variation with MAF ≥0.5% in fine-mapping regions after 1000 Genomes Project imputation. Although we cannot evaluate the impact of rare variation (MAF <0.5%) in established T2D susceptibility loci without large-scale resequencing, our data strongly argue against a role for low-frequency variants of large effect via synthetic association 52 . We have demonstrated that seven distinct association signals, mapping to six T2D susceptibility loci represented on the Metabochip, are likely to be driven by coding alleles, including new index variants mapping to HNF1A and HNF4A. Outside of these regions, our fine mapping confirms previous reports that T2D association signals are primarily driven by noncoding alleles, with effects that are mediated through gene regulation 10, 13, 14, 38 .
We have demonstrated, by genomic annotation and functional assays, that FOXA2 binding assayed by ChIP-seq can be used to pinpoint candidate causal regulatory elements, providing routes to understanding the biology of specific T2D susceptibility loci. These elements highlight variants and effector transcripts through which association signals are mediated, via altered binding of either FOXA2, directly, or another transcription factor. For example, at the MTNR1B locus, the risk allele of the lone credible set variant, rs10830963, preferentially binds NEUROD1 in islet-derived cells in vitro and increases FOXA2-bound enhancer activity in human islet and liver-derived cells. These data are consistent with previous reports correlating the risk allele with higher MTNR1B expression 45, 46 and not loss of function 53 , and they suggest that altered NEUROD1 binding in islets contributes to T2D susceptibility at this locus. Further experiments will be required to confirm our in vitro findings regarding NEUROD1 binding in vivo. However, our attempts to perform ChIP-seq in primary islet samples of the defined MTNR1B genotype were repeatedly unsuccessful, owing to lack of a suitable antibody to NEUROD1. These studies are further complicated by the limited availability of npg A r t i c l e s primary human islets, and the slow division rate of human isletderived cell lines is an impediment to the implementation of genome editing technologies.
FOXA2 is a pioneer factor that binds native chromatin and bookmarks genomic regions for transcriptional activity 54 , and it is involved in pancreatic and hepatic development 55, 56 . FOXA2 is also expressed in other T2D-relevant cell types, such as adipocytes. Future studies will be required to elucidate the extent to which FOXA2 binding events across cell types influence disease risk. Foxa2-null mice have impaired insulin secretion 47 , and common variants at the FOXA2 locus are associated with fasting plasma glucose concentrations 42, 57 . Our findings are thus consistent with the involvement of FOXA2 in maintaining normal glucose homeostasis. Common T2D-associated variants at FOXA2 have also been reported in South Asians 58 , although these variants did not attain genome-wide significant association in the largest GWAS for the disease from multiple ancestry groups [1] [2] [3] [4] [5] and therefore require further replication. Enrichment of FOXA2 binding has also been reported within genomic intervals containing GWAS signals for endocrine, neuropsychiatric, cardiovascular and cancer traits 59 . Our study has the advantage that we consider only the FOXA2 sites that directly overlap variants driving association signals by first fine mapping GWAS loci, thereby providing more targeted credible sets for functional enrichment. Nevertheless, the results of these studies, taken together, suggest a possible role for FOXA2 across a broad spectrum of complex human phenotypes.
In conclusion, we have highlighted that FOXA2 binding patterns can be used to inform future hypothesis-driven investigation of the variants, genes and molecular mechanisms underlying T2D association signals mapping to noncoding sequence. Continued identification of the effector transcripts at these noncoding association signals will require the use of expression quantitative trait locus (eQTL) data and knockout models, in combination with high-throughput experimental data derived from chromatin conformation capture techniques such as capture C. Our findings support the use of transcription factor binding events as a means to partition susceptibility loci, potentially residing in distinct pathways, within disease-relevant cell types. Finally, our study demonstrates the usefulness of fine mapping through integration of genetic and genomic information from relevant tissues and cellular models to elucidate the pathophysiology of complex human diseases, thus offering a promising avenue for the translation of GWAS findings into clinical use.
URLs. DIAGRAM Consortium, http://diagram-consortium.org/; Endocells, http://www.endocells.com/.
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Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html. Table 2 ). To improve the quality of the genotype scaffold in each study, variants were subsequently removed if (i) allele frequencies differed from those for European-ancestry haplotypes from the 1000 Genomes Project Consortium phase 1 integrated reference panel (March 2012 release) 18 by more than 20%; AT/GC variants had MAF >40% because of potential undetected errors in strand alignment; or (iii) MAF was <1%, because of difficulties in calling rare variants. Each scaffold was then imputed up to the phase 1 integrated reference panel (all ancestries; March 2012 release) from the 1000 Genomes Project Consortium 18 , using IMPUTEv2 (ref. 21) or minimac 22 . Within each study, well-imputed variants (IMPUTEv2 info >0.4 or minimac r 2 >0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (Supplementary Table 2) , including principal components to adjust for population structure. Association summary statistics for each variant for each study were corrected for residual population structure using the genomic control inflation factor 60 obtained from 3,598 independent (r 2 <0.05) QT-interval variants, which were not expected to be associated with T2D 4 (Supplementary Table 2 ). We then combined association summary statistics for each variant across studies via fixed-effects inverse variance-weighted meta-analysis. The results of the meta-analysis were subsequently corrected by a second round of QT-interval genomic control (λ QT = 1.18) to account for structure between studies. Variants were excluded from downstream analyses if they were reported in less than 80% of the total effective sample size, defined as N e = 4 × N cases × N controls /(N cases + N controls ), thus removing those that were not well imputed in the majority of studies.
Identification of distinct association signals in established GWAS loci. We used GCTA 23 to select index variants in each of the 39 established loci represented on Metabochip with nominal evidence of association (P J < 0.001) with T2D in an approximate joint regression model. The GCTA model made use of (i) summary statistics from the fixed-effects meta-analysis Metabochip studies and (ii) genotype data for 3,298 T2D cases and 3,708 controls of UK ancestry from GoDARTS as a reference for LD across each fine-mapping region. For comparison, we also obtained association summary statistics for the selected index variants from the GCTA joint regression model on the basis of genotype data from an alternative reference consisting of 4,435 T2D cases and 5,757 controls of Finnish ancestry from FUSION ( Supplementary Fig. 12 and Supplementary Table 15 ). Selected index variants were then carried forward for in silico follow-up in validation meta-analysis.
The validation meta-analysis consisted of 19,662 T2D cases and 115,140 controls from ten GWAS from populations of European ancestry, genotyped with a range of genome-wide arrays (Supplementary Table 1 ). Sample and variant quality control was performed within each study (Supplementary Table 2) . Each scaffold was then imputed up to the phase 1 integrated reference panel (all ancestries; March 2012 release) from the 1000 Genomes Project Consortium 18 , using IMPUTEv2 or minimac. Within each study, well-imputed variants (IMPUTEv2 info ≥0.4 or minimac r 2 ≥0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (Supplementary Table 2) , including principal components to adjust for population structure. Association summary statistics for each variant for each study were corrected for residual population structure using the genomic control inflation factor 60 (Supplementary Table 2 ). We then combined association summary statistics for each variant across studies via fixed-effects inverse variance-weighted meta-analysis.
Association summary statistics for the selected index variants from the Metabochip and validation meta-analyses were next combined via fixed-effects inverse variance-weighted meta-analysis. In each of the 39 established loci represented on the Metabochip, GCTA 23 was used to select index variants with locus-wide evidence of association (P J < 1 × 10 −5 ) in the approximate joint regression model on the basis of (i) summary statistics from the combined meta-analysis and (ii) genotype data for 3,298 T2D cases and 3,708 controls from GoDARTS as a reference for LD across in each fine-mapping region.
For established loci with multiple index variants selected at locus-wide significance from the GCTA approximate joint regression model in combined meta-analysis, we performed exact conditioning within each Metabochip study (Supplementary Table 7) . To obtain the association signal attributed to a specific index variant, high-quality variants (IMPUTEv2 info >0.4 or minimac r 2 >0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (Supplementary Table 2 ) and genotypes at other selected index variants in the fine-mapping region. Association summary statistics for each study were corrected for residual population structure using the QT-interval genomic control inflation factor obtained in the Metabochip meta-analysis. For each association signal, summary statistics for each variant were then combined across discovery studies via fixed-effects inverse variance meta-analysis and subsequently corrected by a second round of QT-interval genomic control (λ QT = 1.18).
Credible set construction.
In an ideal fine-mapping experiment, we would calculate the posterior probability of driving each distinct association signal for all variants mapping to a locus. However, the posterior probability is determined by the association signal effect size of the variant and the corresponding standard error, which is also affected by the quality of imputation across studies, among other factors. To minimize the impact of imputation quality on fine mapping, we therefore retained only variants that were directly typed and/or well imputed in at least 80% of the total effective sample size. Assuming that the variant driving an association signal meets these quality criteria, the probability that it would be contained within the 99% credible set would be ~0.99.
For each distinct signal, we first calculated the posterior probability, π Cj , that the jth variant is driving the association, given by
where the summation is over all retained variants in the fine-mapping region. In this expression,  j is the approximate Bayes factor 61 where β j and V j denote the estimated allelic effect (log(OR)) and corresponding variance from the meta-analysis across Metabochip studies. In loci with multiple distinct signals of association, results are presented from exact conditional meta-analysis after adjusting for all other index variants in the finemapping region. In loci with a single association signal, results are presented from unconditional meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken here to be 0.04 (ref. 61) . The 99% credible set 29 for each signal was then constructed by (i) ranking all variants according to their Bayes factor  j and (ii) including ranked variants until their cumulative posterior probability of driving the association attained or exceeded 0.99.
Genomic annotation data and enrichment analyses. We obtained genomic annotation data for transcription factor binding sites assayed through ChIP experiments from multiple sources. We used sites from the ENCODE Project Consortium 10 for 161 proteins available from the UCSC human genome browser. We also obtained raw ChIP and input sequence data for additional factors assayed in primary pancreatic islets 14 . We then processed these additional factors using protocols employed by the ENCODE Project Consortium 10 . First, sequence reads were aligned to the human genome (hg19) using the Burrows-Wheeler Aligner (BWA) 62 with sex-specific references and were then converted to BAM files using SAMtools 63 after removing duplicate reads and those not uniquely mapped. Binding sites were called from reads of each replicate, as well as reads pooled across all replicates, using SPP 64 . The raw sites from each replicate of a protein were compared using an irreproducible discovery rate 65 (IDR) threshold of 0.02. The resulting number of sites passing this IDR threshold was then used to filter the pooled sites of a protein. The set of sites was further filtered for artifacts using a blacklist of genomic regions from the ENCODE Project Consortium. Sites from all sources for each protein, including ENCODE, were then combined. The complete set of 165 proteins employed in these analyses is presented in Supplementary Table 11 . In addition, we obtained FOXA2 ChIP-seq sites that were previously identified in human liver 39 and converted their positions to hg19 coordinates.
We obtained annotation data for five histone modifications (H3K4me1, H3K4me3, H3K27ac, H3K36me3 and H3K27me3) and CTCF binding assayed from ChIP experiments. We used data from nine cell types from ENCODE 10 (GM12878, K562, HepG2, HSMM, HUVEC, NHEK, NHLF, H1-hESC and HMEC); we also obtained raw ChIP data assayed in primary pancreatic islets 14 and premature and mature human adipose stromal cells 66 . We mapped reads to the hg19 reference genome using BWA 62 and used the resulting mapped reads from these 12 cell types as input to ChromHMM 67 . We assigned states on the basis of the following chromatin signatures: active promoter (H3K4me3 and H3K27ac); strong enhancer 1 (H3K4me3, H3K27ac and H3K4me1); strong enhancer 2 (H3K27ac and H3K4me1); weak enhancer (H3K4me1); poised promoter (H3K27me3, H3K4me3 and H3K4me1); repressed (H3K27me3); insulator (CTCF); and transcription (H3K36me3). For each cell type, we pooled the three enhancer states into one enhancer category and the two promoter states into one promoter category. We also identified long noncoding RNA data from the Human Body Map (UCSC Genome Browser) and from pancreatic islets 68 .
For each genomic annotation, we tested for overall enrichment of the posterior probability that overlapping variants in the 99% credible sets are driving distinct association signals (π C ). We first calculated the mean posterior probability (mean π C ) over the set of variants overlapping a given annotation. We then generated a null distribution of the mean posterior probability (mean π C ) by (i) shifting the genomic locations of binding sites a random distance within 100 kb in either direction; (ii) recalculating the mean posterior probability for 99% credible set variants overlapping shifted sites; and (iii) repeating this procedure 100,000 times. We estimated the fold enrichment of each overlap by calculating the expected null posterior probability and dividing the observed probability by the expected probability. We calculated a P value for the enrichment by the proportion of permutations for which the expected posterior probability of driving the association signal was greater than or equal to that observed. We considered cell type annotations to be significantly enriched if the P value was less than 0.05/37 = 0.0014 (Bonferroni correction for 37 annotations). We considered transcription factor binding site annotations to be significantly enriched if the P value was less than 0.05/165 = 0.00030 (Bonferroni correction for 165 factors). We next partitioned binding sites into those that are shared with another factor (where the genomic interval intersects a site for at least one other factor) and those that are unique. We also partitioned binding sites on the basis of overlap with islet enhancer elements. For each factor with significant enrichment across all credible sets (FOXA2), we applied the same enrichment analysis but restricted to credible set variants for each distinct association signal, separately.
We assessed the evidence for intersection in FOXA2 ChIP-seq sites from islets 14 , HepG2 cells 10 and liver 39 , across the genome and overlapping credible set variants, using BEDtools 69 .
Motif analysis. We conducted recognition motif enhancement analyses for the set of FOXA2 ChIP-seq binding sites. First, we obtained the repeat-masked genomic sequence underlying each site using the UCSC human genome browser. We scanned sequences for enrichment in these motifs using MEMEChIP 70 , which uses up to 100 bp surrounding the midpoint of each site. This resulted in 198 enriched motifs with an E value (expected number of hits) less than 0.05 (Supplementary Table 16) . We compared each motif to those known from JASPAR 71 , ENCODE 10 and Homer 72 using Tomtom 73 .
Second, we identified variants in FOXA2 ChIP-seq sites predicted to disrupt an enriched recognition motif by (i) scanning the 25 bp of sequence flanking each variant allele using FIMO 74 (P < 0.0001) and (ii) retaining variants in highly conserved positions (entropy less than 0.5). For the 12 variants at FOXA2-enriched signals disrupting at least one recognition motif ( Table 3 and the credible set for the association signal for that locus (by lifting over from hg19 to mouse build mm10). Second, for each distinct association signal, we identified the closest gene to the index variant using BEDtools 69 . We then partitioned distinct association signals into those with evidence for enriched FOXA2 binding (fold enrichment >1) and those without, counting each gene only once in a given group. For each analysis, we converted the fold changes to percentages and compared the percent change in expression using a onesided Wilcoxon rank-sum test between genes in each partition and all 4,629 protein-coding genes.
